News Archive

Walbrook PR Welcomes GENinCode to AIM

22 July 2021

Walbrook PR, which provides high quality Financial PR and Investor Relations to Small Cap and AIM listed companies, announces it has acted as Financial PR & Investor Relations advisor for the AIM IPO of GENinCode plc (AIM: “GENI”), the cardiovascular disease ("CVD") company focused on predictive genetics for the prevention of cardiovascular disease. The team at Walbrook will now manage the Company’s communications with the financial media, research analysts and non-institutional investors, including new and existing private investors.

On admission, GENinCode plc completed a successful placing for gross proceeds of £17 million before expenses, with a market capitalisation of approximately £42.2 million.

The Company was incorporated in September 2018 to acquire the assets, intellectual property and know-how of the Ferrer inCode and Gendiag.exe businesses, which were then part of Grupo Ferrer Internacional S.A., a large Spanish multinational private pharmaceutical and healthcare company.

The technology and products acquired included:

  • Cardio inCode® - assesses the coronary genetic risk and cardiovascular risk stratification
  • Lipid inCode® - diagnoses and manages hypercholesterolemia
  • Thrombo inCode® - diagnoses and manages genetic thrombophilia and thrombosis risk
  • Sudd inCode® - disgnoses the cause of sudden cardiac death and familial heart disease

 The Directors believe that approximately €50 million has been invested in the research and development of these products since 2007. The Company has begun to commercialise these products in certain European countries and is also targeting the UK and US. 

The Directors expect Cardio inCode®, Lipid inCode® and Thrombo inCode® (all CE-Marked) to be the primary products of commercialisation focus over the immediate term.

Paul McManus, Founder and Managing Director of Walbrook PR, commented: “We are delighted to work with GENinCode and congratulate the Company on their AIM IPO today. The Company’s innovative polygenic product portfolio has significant potential to improve the early diagnosis of cardiovascular disease, currently the leading cause of death worldwide.

“We look forward to developing the Company’s profile with analysts, investors and journalists as they begin this exciting new chapter.”


For more information visit the Company’s website:

For further information please contact:

Paul McManus Tel: 020 7933 8787 Mob: 07980 541 893 [email protected]
[email protected]  


About Walbrook PR:                                                                                                                                  

Walbrook PR was founded in April 2009 by Paul McManus and focuses on providing high quality Financial PR and Investor Relations to Small Cap and AIM listed companies.

Walbrook PR is ranked #2 by number of AIM listed companies with 50 AIM listed clients (Source: AIM Advisers Rankings Guide, October 2021) and ranked #7 by total number of stock market listed clients (Corporate Advisers Rankings Guide, August 2021) advising a total of 58 stock market listed companies across a wide mix of sectors.

Walbrook PR prides itself on having a strong reputation for working with growing UK Small Cap and AIM listed companies; a proven IR offering, which focuses on the Private Client Investment Management community and the retail investment community; and on having a proactive, hands-on approach from a committed team with full ownership of the business. 

Who We Work With